Trevor Clancy

Trevor Clancy is a prominent figure in the field of bioinformatics and cancer immunotherapy, with a significant role at NEC OncoImmunity AS. Here's a comprehensive overview of his professional background:

Professional Experience

Trevor Clancy has held several key positions throughout his career:

NEC OncoImmunity AS:

• Co-founder and Chief Scientific Officer (CSO)14
• Advisor (current role)1

Nagasaki University:

• Professor (2023 - present)3

Institute for Cancer Research:

• Scientist3

Education

Clancy has a strong academic background in bioinformatics and biochemistry:

• Doctor of Philosophy (Ph.D.) in Bioinformatics (2008 - 2011)3
• Master of Science (M.Sc.) in Bioinformatics (2002 - 2003)3
• Bachelor of Science (B.Sc.) in Biochemistry (1997 - 2001)3

Research and Expertise

Trevor Clancy is an accomplished researcher in the field of bioinformatics and cancer immunotherapy:

• His work focuses on neoantigen prediction for personalized cancer immunotherapy and infectious disease vaccines1
• He has a significant publication record, with over 1,400 citations and an h-index of 212
• Clancy's research involves the application of artificial intelligence and machine learning in biotech1

Recent Developments

• In December 2023, Clancy announced his departure from the CSO role at NEC OncoImmunity AS after a 10-year journey with the company4
• He continues to serve as an advisor to NEC OncoImmunity AS1

Trevor Clancy's LinkedIn username is indeed trevor-clancy-55a351, as mentioned in the query.5